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Summary
Lung transplantation has become a life-saving procedure for individuals with variety of 
end-stage respiratory diseases. Optimal immunosuppression remains the key to long-term graft 
survivival. The protocols for immunosuppressive therapy following lung transplantation can be 
divided into three general categories: induction, maintenance, and treatment of rejection. The 
goal of induction therapy is to provide intense immunosuppression in the early post-transplan-
tation period, when the risk of allograft rejection is the highest. Induction agents primarily tar-
get T lymphocytes, which are considered the effector cells in cell-mediated rejection. Current 
maintenance therapy typically includes a calcineurin inhibitor, nucleotide blocking agent and 
corticosteroid. Pulse steroids are generally the first treatment of acute cellular rejection. Therape-
utic modalities for treatment of refractory cellular rejection include switch from cyclosporine to 
tacrolimus, use of lymphocyte depleting agents, azithromycine, and extracorporeal photophere-
sis. Treatment options for humoral rejections include plasmapheresis and immunoglobulines in 
combination with rituximab.
Keywords: lung transplantation; immunosuppression; induction therapy;  maintenance the-
rapy; rejection.
INTRODUCTION
Lung transplantation has become a life-saving procedure for individuals with 
variety of end-stage respiratory diseases. The success of transplantation has been 
closely related to descovery of effective imunosuppressive regimens. In the early 
1980s, the introduction of ciclosporin as the mainstay of maintenace immunosu-
ppression was followed by a significant improvement in the survival of lung tran-
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splant recipients. Immunosuppressive regimes are employed to reduce the rate of 
acute and chronic rejection. Adverse effects of immunosupressive therapy inclu-
de drug-specific toxicities, opportunistic infections and malignancy. Risk of those 
events directly correlates with the degree of overall immunosuppression. Therefore, 
immunosuppressive protocols try to achieve delicate balance between risk of adver-
se events  and rejection. General principle is that the highest concentrations of im-
munosuppressants are targeted in the early post-transplant period when the risk of 
acute rejection is the greatest. Immunosuppression is slowly decreased over time (as 
the risk of acute rejection decreases) to help lower adverse effects. Protocols are con-
sisted of several drugs. Combination therapy targets several steps in T-cell activati-
on, allowing lower doses of each individual drug which provide higher tolerability.
Immunosuppressive regimes are generally defined as induction, maintenance, 
and treatment of rejection.
Induction therapy
Despite the advances in immunosuppressive therapy, acute allograf rejection is 
still a significant problem in lung transplantation. More than a third of lung tran-
splant recipients are treated for acute rejection in the first transplant year [1]. The ra-
tionale of induction therapy is to use the strongest immunosuppressive drugs at the 
time when the risk of rejection is highest, which is in the first few weeks following 
transplantation. Induction regimes consist of agents which primarily target T lymp-
hocytes, which are considered the effector cells in cell mediated rejections. Most 
frequently used antilymphocytic agents are polyclonal antilymphocyte antibodies, 
interleukin-2 receptor antagonists and anti-CD52 antibodies (alemtuzumab). Induc-
tion therapy also allows later introduction of nephrotoxic immunosuppressive dru-
gs in patients with compromised renal function.
Polyclonal anti-lymphocyte antibodies (ATG)
Polyclonal antibodies are derived from immunization of horses (ATGAM) or ra-
bbits (Thymoglobulin) with human tymocytes. These preparations contain antibo-
dies directed againts many surface T- and B-cell antigens. Antithymocyte globulin 
depletes circulating lymphocytes through multiple mechanisms, including comple-
ment-mediated lysis and opsonization in the spleen and liver [2]. The major acu-
te side effects include: cytokine release syndrome, serum sickness reaction, while 
some patients experience true anaphylaxis. The glucocorticoids, antihistamines, an-
tipyretics are used for prophylaxis. Leukopenia and thrombocytopenia may require 
either a reduction in dose or termination of therapy.
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Based on the analysis of International Society of Heart and Lung Transplanta-
tion (ISHLT) data, ATG - induction significantly reduced the incidence of acute re-
jection (AR) during the first post-transplantation year, compared to no induction [3]. 
Also, after 2 years, a trend toward a lower incidence of the bronchiolitis obliterans 
syndrome (BOS) was documented in the ATG-group (20%) versus the non-induction 
arm [4]. ATG induction therapy results in significany lower incidence of acute rejec-
tions without an increase in infection complications [5].
Interleukin-2 receptor antagonists (IL2RA)
Interleukin-2 receptor antagonists are monoclonal antibodies that selectively 
bind to the alpha subunit of the IL-2 receptor (CD25) on activated T cells. By binding 
this cell surface receptor, these antibodies inhibit T cell proliferation and diferenti-
ation without T cell depletion. In contrast to polyclonal antibody preparations, IL-2 
receptor antagonists show fewer side effects and are well tolerated.
Induction therapy with IL2RA reduces or delays the incidence of acute rejection, 
bronchiolitis obliterans syndrome (BOS), and may improve graft and patient survi-
val compared to no induction [4,6].
Alemtuzumab
Alemtuzumab is a humanized rat monoclonal antibody that targets the CD52 
antigen expressed on both T and B cells. It leads to depletion of T cells through com-
plement - mediated and direct cellular cytotoxicity [7]. The usual dose of alemtuzu-
mab for induction of immunosuppression is 30 mg i.v. Alemtuzumab can precipitate 
cytokine storm so patient should be pretreated with steroids. Although alemtuzu-
mab has a half life of 12 days, inflammatory cells needs significantly longer time of 
recovery after alemtuzumab therapy. B cells recover at 12 months, while 50% reco-
very of T cells is usually reached at 36 months [8]. If alemtuzimab is administered, 
the maintenance dose of immunosupressive therapy is tailored in a way that tacro-
limus is reduced by 40% of standars target values, while steroids are reduced to 30% 
of standard dose. Mycophenolate mofetil (MMF) is avoided in the first postoperative 
year for the risk of severe laeukopenia.
Maintenace therapy
Maintenance immunosuppressive therapy is administered to transplant reci-
pients to help prevent acute and chronic allograft rejection. Maintenance therapy 
generally consists of combined therapy with a calcineurin inhibitor, a nucleotide 
blocking agent (antimetabolite), and steroids.
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Calcineurin-inhibitors (CNI)
Since the induction of cyclosporine in the early 1980s, the calcineurin ‒ inhi-
bitors serve as the backbone of maintenance immunosuppressive therapy in solid 
organ transplantation.Calcineurin - inhibitors include cyclosporin (CsA) and tacro-
limus (TAC).
Cyclosporine (CsA)
Cyclosporine acts by binding to cyclophilin, an intracellular protein. The com-
plex inhibits the activity of calcineurin, which is responsible for the transcription 
of IL-2 and several other cytokines including TNF-alpha, granulocyte-macrophage 
colony ‒ stimulating factor and interferon gamma. This prevents activation and pro-
liferation of CD4+ T cells [9].
Drug dosage should be adapted according to the monitoring trough level. Tar-
geted trough levels are 250 ‒ 350 ng/ml in the first post-transplantation year, and 
should be reduced by 40% in patients who received alemtuzumab induction thera-
py. Target drug concentrations are typically reduced over time as the risk of acute 
rejection decreases. The common side effect of cyclosporine, which are related to 
the concentration of the drug, include nephrotoxicity, hypertension, hyperlipide-
mia, gingival hyperplasia, hirsutism, and tremor. Nephrotoxicity, the major adverse 
effect of cyclosporine, results from vasoconstriction of the afferent glomerular ar-
terioles.
Tacrolimus (TAC)
TAC was previously known as FK506. It is a macrolide and is produced by the 
fungus Streptomyces tsukubaensis. TAC binds to the cytoplasmic immunophilin, 
FK binding protein12, and inactivates calcineurin. Through this pathway it inhibits 
interleukin ‒ 2 and interferon ‒ gamma production and subsequently T-cell prolife-
ration and activation.
Toxicity profile of tacrolimus is similar to that of cyclosporin A, but it is less 
nephrotoxic. Recently, tacrolimus has been found to be superior to cyclosporin A in 
lung transplantation in terms of decreased incidences of acute rejection and chronic 
rejection [10]. Therefore, the use of tacrolimus has increased steadily, and the drug 
is now the dominant calcineurin inhibitor.
TAC may be administered as a continuous infusion, or orally. The drug dose 
should be adjusted as per blood levels. The target levels in the first three postopera-
tive months are 15-18 ng/ml. Therapy is gradually decreased over time, with tacroli-
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mus target levels at 8 to 10 ng/mL in a second postoperative year, and 8 ng/ml three 
years after transplantation. In patients who had received alemtuzumab induction 
therapy, tacrolimus target levels should be reduced by 40%.
Nucleotide blocking agents
Azathioprine (AZA) and mycophenolate mofetil (MMF) are commonly used 
nucleotide blocking agents after lung transplantation. Most transplant centers use 
mycophenolat mofetil as a part of maintenance immunosuppressive therapy, due to 
its increased selectivity for T- and B- lymphocytes [11].
Mycophenolate mofetil (MMF)
The mechanism of action of MMF is via selective inhibition of T- and B-cell pro-
liferation. Mycophenolate reversibly inhibits de novo synthesis of purines during 
the S phase, a step that is required for the lymphocyte cell division. T and B lymp-
hocytes use only de novo pathway in purine biosynthesis, whereas other cell lines 
that use both de novo and salvage pathways are not inhibited [12]. Mycophenolate’s 
principal toxicities occur in the gastrointestinal tract and principally manifest as na-
usea and diarrhea. Due to potent myelosuppression, careful monitoring of complete 
blood counts should be performed on regular basis. MMF may be administered eit-
her orally or intravenously. The usual dosing schedule is 1000 mg. orally given twice 
daily. Drug levels can be monitored, although this is not done routinely.
Steroids
Corticosteroids are employed during induction, maintenance and anti-rejection 
therapy in pulmonary transplantation, emphasizing their crucial role in modula-
ting the host immune response. They suppress prostaglandin synthesis, reduce hi-
stamine/bradykinin release, decrease vascular permeability and down-regulate key 
cytokines by influencing gene transcription [13]. Most common side effects include 
impaired glucose tolerance, hyperlipidemia, hypertension, hirsutism, M. Cushing, 
osteoporosis. High-dose steroids are generally administered intraoperatively and 
postoperatively. Due to the long-term side effects, the corticosteroid dose should 
be gradual tapering over months. The prednisone dose in the first 3 postoperative 
month is 0.3 mg/kg body weight, while after first post-transplant year the predniso-
lone dose is 5 mg once a day.
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Tretment of acute and chronic rejection
Rejection therapy refers to immunosuppressive therapy given to reverse an epi-
sode of rejection. The intensity and type of rejection therapy depend on the severity 
of the rejection and type of rejection (whether it is cellular mediated or humoral).
Pulse steroids (500 ‒ 1000 mg/d of methylprednisolone for 3-5 d followed by ste-
roid taper over the ensuring 2-3 weeks) are generally the first treatment for cellular 
allograft rejection. Despite the many therapeutic options described above, refrac-
tory acute and chronic rejection alities in lung transplantation. An internationale 
retrospective study comparing CsA to tacrolimus revealed a decreased incidence in 
acute rejection and reversal of refractory acute rejection episodes and improvement 
of lung function after conversion of CsA to tacrolimus [14]. Therefore, for patients on 
the cyclosporine based regimen with evidence of rejection, most transplant centers 
reccommend switch maintenance immunosuppressive agent from cyclosporine to 
tacrolimus.
Azithromycin is a macrolide antibiotic with anti-inflammatory and immuno-
modulatory properties. Early initiation of azithromycin in lung transplant recipi-
ents may prevent the incidence of BOS and prolong BOS free survival. It may impro-
ve or stabilize pulmonary function after the onset of BOS, particularly in those with 
neutrophil and IL-8 predominant BAL [15].
In a case of a refractory cellular rejection, lymphocyte depleting agents (ATG or 
alemtuzumab) are used. ATG may decrease or stop the decline of lung function in 
patients presenting with BOS [16].
Other treatment modalities for refractory cellular rejection include extracorpo-
real photopheresis (ECP). ECP involves leukopheresis followed by incubation of iso-
lated cells with 8-methoxypsoralen and subsequent exposing the cells to ultraviolet 
light in the presence of 8-methoxypsoralen. The cells are than reinfused to the pa-
tient. ECP is thought to induce apoptosis of the mononuclear cells, resulting in im-
munologic processing of cellular components after re-injection into the circulation 
that leads to the production of tolerogenic T-lymphocytes [17,18).
Treatment options for humoral rejections include plasmapheresis (5-6 cycles) 
and immunoglobulines (1-2g/kg over 3-6 days) in combination with rituximab.
Lung transplantation continues to offer patients with end-stage respiratory di-
seases chance for better quality and lenght of life. A better understanding of the 
immune response has led to improved monitoring of rejection and the development 
of better immunosuppressive regimes. In the future, advances inimmunosuppressi-
on protocols and the use of more specific immune monitor tools are likely to lead to 
significant improvements in outcomes.
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Sažetak
Imunosupresivno liječenje nakon transplantacije pluća
Transplantacija pluća je postupak koji spašava život bolesnicima s krajnjim stadijem razli-
čitih plućnih bolesti. Optimalna imunosupresija predstavlja ključ dugotrajnog preživljenja pre-
sadka. Protokoli imunosupresivnog liječenja nakon transplantacije pluća mogu se podijeliti u tri 
glavne grupe: indukcijska terapija, terapija održavanja i terapija liječenja reakcija odbacivanja. 
Cilj indukcijske terapije je osigurati intenzivnu imunosupresiju u ranom posttransplantacijskom 
periodu, kada je rizik odbacivanja alografta najveći. Indukcijski lijekovi su primarno usmjereni 
na T limfocite, koji se smatraju glavnim stanicama u stanično posredovanoj reakciji odbacivanja. 
Trenutno se terapija održavanja tipično sastoji od inhibitora kalcineurina, antimetabolita i korti-
kosteroida. Pulsne doze kortikosteroida su prvi izbor liječenja akutnog staničnog odbacivanja. 
Načini liječenja refraktornog staničnog odbacivanja uključuju zamjenu ciklosporina takrolimu-
som, primjenu monoklonalnih i poliklonalnih antilimfocitnih protutijela, azitromicina i ekstra-
korporalne fotofereze. Mogućnosti liječenja humoralnog odbacivanja uključuju plazmaferezu i 
imunoglobuline u kombinaciji s rituksimabom.
Ključne riječi: transplantacija pluća; imunosupresija; indukcijska terapija; terapija održava-
nja; odbacivanje.
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